All In Biotech

Drug Trial Radar · NCT04230148

Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

A Phase IV, Multi-center, Open-label Study to Determine the Safety, Tolerability and Clinical Outcomes Following Oral Administration of EGATEN™ (Triclabendazole) in Patients (6 Years of Age or Older) With Fascioliasis.

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

301

Actual

Start

Feb 11, 2022

Primary completion

Mar 27, 2026

Study completion Mar 27, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study evaluated safety and tolerability along with clinical outcomes of Egaten administered as per the FDA approved dosing regimen of 2 doses of 10 mg/kg (given approximately 12 hours apart) in Fascioliasis participants (≥ 6 years of age).

Conditions

  • Fascioliasis

Interventions

  • Egaten (Triclabendazole) 250 mg tabletsDrug

    Egaten 250 mg scored tablets for oral use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Adverse events were reported from the first dose of study treatment until approximately 90 days thereafter.

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia

  • Novartis Investigative Site

    Alexandria, Egypt

  • Novartis Investigative Site

    Cairo, Egypt, Egypt

  • Novartis Investigative Site

    Cusco, Peru

  • Novartis Investigative Site

    San Martín de Porres, Lima region, Peru

  • Novartis Investigative Site

    Sur, Turkey (Türkiye)

  • Novartis Investigative Site

    Van, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Fatih, Turkey (Türkiye)

  • Novartis Investigative Site

    Gaziantep, Sehitkamil, Turkey (Türkiye)

  • Novartis Investigative Site

    Qui Nhon, Binh Dinh, Vietnam

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.